TG1050, A viral-vector based immunotherapeutic designed to treat chronic hepatitis B induces immune responses similar to those display by HBV resolving patients and has an early antiviral effects in a HBV tolerant model.

Perrine Martin, et al. Hepatology, 2013, (58) S1, 222A–225A – [...]